key: cord-0970961-trxvzw1a authors: Thwe, Phyu M.; Ren, Ping title: Analysis of sputum/tracheal aspirate and nasopharyngeal samples for SARS-CoV-2 detection by laboratory-developed test and panther Fusion system date: 2020-09-30 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2020.115228 sha: 7873240a85306203909601cf4ce0ff89f7076a92 doc_id: 970961 cord_uid: trxvzw1a In this study, 127 sputum/tracheal aspirate specimens were evaluated by a laboratory-developed real-time RT-PCR method and Fusion SARS-CoV-2 assay. These specimens were collected from the patients who have nasopharyngeal swab (NPS) samples being used for SARS-CoV-2 detection previously or simultaneously. The overall agreement was 96% between the lower respiratory tract (LRT) and NPS samples, suggesting that LRT specimens could be an option for patients who develop a productive cough or those receiving invasive mechanical ventilation. Diagnostic testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from nasopharyngeal (NPS) and oropharyngeal (OP) swabs were the first FDA approved sample types to be used on laboratory-developed tests (LDT) or commercial platforms. The Centers for Disease Control and Prevention (CDC) stated that lower respiratory tract (LRT) samples, such as sputum, are permissible for patients with a productive cough or under special circumstances (e.g., invasive mechanical ventilation) (1). Testing sputum can also be helpful for patients under investigation (PUI), whose NPS are negative for SARS-CoV-2. Previous studies have shown that SARS-CoV-2 RNA could be detected in non-NP sample types, such as sputum, bronchoalveolar (BAL) fluid, and saliva (2, 3, 4) . Here, we examined the potential utilization of sputum/tracheal aspirate (collectively as sputum) samples for diagnosis of coronavirus disease 2019 (COVID-19) by real-time RT-PCR using LDT and Fusion SARS-CoV-2 assay (Hologic, San Diego, CA). The LDT had previously been established in our laboratory for NPS in March 2020. The Fusion assay was modified from the Emergency Use Authorization (EUA) approved protocol by using dithiothreitol treated sputum after 1:1 water dilution. One hundred and twenty-seven (127) retrospective sputum samples from 103 in-patients were collected. NPS samples from these 103 patients were tested for initial diagnosis of COVID-19, whereas sputum samples were collected at the time of NPS collection and/or during hospitalization. Out of 103 patients, 73 sputum samples were from 48 NPS-positive patients whereas 54 were from 54 NPS-negative patients (Table 1) We demonstrated a 100% negative agreement for NPS-sputum negative pairs (54/54) and a 93% (95%CI: 85 -98%) positive agreement for NPS-sputum positive pairs (68/73) by LDT (Table 2 ). The overall agreements between NPS and sputum pairs were 96% (95% CI: 91 -99%) and 90% (95%CI: 78 -96%) for LDT and Fusion, respectively. Due to a limited supply of Fusion reagents, the sample size for Fusion was smaller than LDT, which likely resulted in a slightly lower agreement than LDT. The ĸ values were 0.92 (95% CI: 85.2 -98.9%) and 0.80 (95% CI: 64 -96%) for LDT and Fusion, respectively, indicating that the agreements were almost perfect to substantial. The results from all samples tested on Fusion correlated with LDT. The LoD were determined to be 10,000 and 3,000 copies/mL for LDT and Fusion method on sputum samples, respectively. We demonstrated that sputum is one of the alternative specimen types for SARS-CoV-2 diagnosis in the hospitalized patient population. The discrepancy (i.e., positive NPS and negative sputum) could be attributed to i) poor quality of sputum and ii) sample collection at the disease recovery stage. One of the potential issues with sputum is the presence of mucus which poses difficulty during sample preparation, particularly on automated platforms. For Fusion SARS-CoV-2 assay, the manufacturer discourages the mucus part of LRT samples being transferred into Fusion lysis tubes. Despite the 1:1 dilution of sputum in sterile water (leftover samples from LDT performance), the persistent viscosity deterred successful handling by the Panther Fusion instrument. We have overcome these issues, by applying the CDC guidelines for sputum preparation and successfully demonstrated that sputum can be validated on any platform, whether it is a manual or an automated instrumentation system. Therefore, testing of sputum may be necessary for a certain patient population indicated below. A testing algorithm for sputum may need to be developed with the support of infectious disease clinicians. We believe that our findings are beneficial in cases of i) hospitalized individuals with endotracheal intubation before the NPS samples could be taken for COVID-19 evaluation (endotracheal aspiration may be indicated in this situation); ii) patients with a traumatic fracture to the facial/nasal area or anatomic anomaly; iii) symptomatic patients who have a productive cough with negative NPS results. One pitfall of sputum collection is the generation of aerosols; therefore, induced sputum is not recommended by the CDC. However, endotracheal sputum aspirates or self-collected sputum (with proper instructions) in a defined patient population would provide several advantages over NPS, such as the discomfort associated with NPS sampling. To our knowledge, this is the first study analyzing the use of sputum on LDT and Fusion platforms. Overall, we have demonstrated that both platforms are validated and can be utilized for the diagnosis of COVID-19 from sputum samples in symptomatic patients. J o u r n a l P r e -p r o o f Detection of SARS-CoV-2 in Different Types of Clinical Specimens SARS-CoV-2 detection in different respiratory sites: A systematic review and meta-analysis Differences of SARS-CoV-2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens Among Adult Inpatients With COVID-19 Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR Hologic Panther Fusion  SARS-CoV-2. Package Insert. Accessed The measurement of observer agreement for categorical data SARS-CoV-2 Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19 Virological assessment of hospitalized patients with COVID-2019 The project is approved by the UTMB Institutional Review Board (IRB) under an expedited review process with IRB # 20-0143. Not applicable.